Is PRAX or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Trevi Therapeutics N/A -24.53% -23.37%

Does the media prefer PRAX or TRVI?

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of 0.25 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IBRX or TRVI?

In the previous week, ImmunityBio had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat ImmunityBio's score of 0.05 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or QGEN?

In the previous week, Qiagen had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Qiagen's score of 0.43 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NUVL or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is NUVL or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Trevi Therapeutics N/A -24.53% -23.37%

Does the media prefer NUVL or TRVI?

In the previous week, Nuvalent had 38 more articles in the media than Trevi Therapeutics. MarketBeat recorded 40 mentions for Nuvalent and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Nuvalent's score of 0.19 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 14 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TRVI or PCVX?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is TRVI or PCVX more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Vaxcyte N/A -32.51% -29.51%

Does the media favor TRVI or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Trevi Therapeutics. Vaxcyte's average media sentiment score of 1.11 beat Trevi Therapeutics' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trevi Therapeutics (TRVI) Competitors

$13.40 -0.19 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$13.20 -0.21 (-1.53%)

As of 07:19 PM Eastern

Compare

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

Should you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include Praxis Precision Medicines (PRAX), ImmunityBio (IBRX), Qiagen (QGEN), Nuvalent (NUVL), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Trevi Therapeutics	N/A	-24.53%	-23.37%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Trevi Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	784.75	-$303.27M	-$13.37	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of 0.25 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines presently has a consensus target price of $572.72, suggesting a potential upside of 137.98%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 70.90%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Summary

Trevi Therapeutics beats Praxis Precision Medicines on 8 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 103.44%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 70.90%. Given ImmunityBio's higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics has lower revenue, but higher earnings than ImmunityBio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	64.53	-$351.40M	-$0.85	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, ImmunityBio had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat ImmunityBio's score of 0.05 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Summary

Trevi Therapeutics beats ImmunityBio on 10 of the 15 factors compared between the two stocks.

How does Trevi Therapeutics compare to Qiagen?

Trevi Therapeutics (NASDAQ:TRVI) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Qiagen has a net margin of 19.16% compared to Trevi Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Qiagen	$2.09B	3.65	$424.88M	$1.91	19.39

Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Trevi Therapeutics currently has a consensus price target of $22.90, indicating a potential upside of 70.90%. Qiagen has a consensus price target of $44.98, indicating a potential upside of 21.46%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Trevi Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Qiagen had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Qiagen's score of 0.43 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevi Therapeutics beats Qiagen on 8 of the 15 factors compared between the two stocks.

How does Trevi Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Nuvalent presently has a consensus target price of $131.15, indicating a potential upside of 6.32%. Trevi Therapeutics has a consensus target price of $22.90, indicating a potential upside of 70.90%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Nuvalent had 38 more articles in the media than Trevi Therapeutics. MarketBeat recorded 40 mentions for Nuvalent and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Nuvalent's score of 0.19 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	14 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Summary

Trevi Therapeutics beats Nuvalent on 10 of the 13 factors compared between the two stocks.

How does Trevi Therapeutics compare to Vaxcyte?

Trevi Therapeutics (NASDAQ:TRVI) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Vaxcyte had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Trevi Therapeutics. Vaxcyte's average media sentiment score of 1.11 beat Trevi Therapeutics' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Trevi Therapeutics' return on equity of -24.53% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Vaxcyte	N/A	-32.51%	-29.51%

Trevi Therapeutics presently has a consensus price target of $22.90, indicating a potential upside of 70.90%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 89.34%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Trevi Therapeutics beats Vaxcyte on 8 of the 13 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.93B	$3.28B	$6.41B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	N/A	18.99	24.46	23.62
Price / Sales	N/A	290.48	500.50	105.26
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	9.37	8.00	10.43	6.70
Net Income	-$42.76M	$23.89M	$3.56B	$337.26M
7 Day Performance	-0.37%	-3.49%	-1.39%	-1.41%
1 Month Performance	-7.59%	1.03%	0.86%	1.15%
1 Year Performance	105.84%	34.39%	19.42%	22.61%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	2.5936 of 5 stars	$13.40 -1.4%	$22.90 +70.9%	+112.0%	$1.93B	N/A	N/A	20
PRAX Praxis Precision Medicines	2.7733 of 5 stars	$272.00 +5.4%	$572.72 +110.6%	+462.4%	$7.58B	$8.55M	N/A	110
IBRX ImmunityBio	2.9961 of 5 stars	$7.10 -1.8%	$14.20 +100.0%	+110.8%	$7.44B	$113.29M	N/A	590
QGEN Qiagen	4.6028 of 5 stars	$35.91 +0.6%	$44.98 +25.3%	-22.3%	$7.40B	$2.09B	18.75	5,654	Short Interest Decrease
NUVL Nuvalent	1.8476 of 5 stars	$91.72 +0.4%	$141.24 +54.0%	+62.0%	$7.25B	N/A	N/A	40	Trending News Analyst Downgrade Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Summary

How does Trevi Therapeutics compare to Qiagen?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Summary

How does Trevi Therapeutics compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. PRAX, IBRX, QGEN, NUVL, and PCVX

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Is PRAX or TRVI more profitable?

Do insiders & institutionals have more ownership in PRAX or TRVI?

Which has preferable valuation & earnings, PRAX or TRVI?

Does the media prefer PRAX or TRVI?

Do analysts prefer PRAX or TRVI?

Which has more volatility and risk, PRAX or TRVI?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Do analysts recommend IBRX or TRVI?

Which has better earnings and valuation, IBRX or TRVI?

Does the media refer more to IBRX or TRVI?

Do insiders & institutionals have more ownership in IBRX or TRVI?

Which has more volatility and risk, IBRX or TRVI?

Is IBRX or TRVI more profitable?

Summary

How does Trevi Therapeutics compare to Qiagen?

Is TRVI or QGEN more profitable?

Which has stronger valuation and earnings, TRVI or QGEN?

Which has more volatility & risk, TRVI or QGEN?

Do analysts prefer TRVI or QGEN?

Do insiders and institutionals believe in TRVI or QGEN?

Does the media favor TRVI or QGEN?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Do analysts rate NUVL or TRVI?

Does the media prefer NUVL or TRVI?

Do institutionals & insiders believe in NUVL or TRVI?

Which has more volatility & risk, NUVL or TRVI?

Which has stronger valuation & earnings, NUVL or TRVI?

Is NUVL or TRVI more profitable?

Summary

How does Trevi Therapeutics compare to Vaxcyte?

Does the media favor TRVI or PCVX?

Which has more risk and volatility, TRVI or PCVX?

Which has better earnings and valuation, TRVI or PCVX?

Is TRVI or PCVX more profitable?

Do analysts recommend TRVI or PCVX?

Do insiders and institutionals believe in TRVI or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools